Verity Research Inc

1. Pfizer Inc. $176,602 52 payments
2. Takeda Pharmaceuticals U.S.A., Inc. $118,351 21 payments
3. Allergan Inc. $95,069 22 payments
4. Gilead Sciences, Inc. $58,878 22 payments
5. Braintree Laboratories, Inc. $31,744 9 payments
6. Adare Pharmaceuticals, Inc. $25,664 9 payments
7. Janssen Research & Development, LLC $3,611 2 payments

1. A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis ENTERPRET $101,255 14 payments
2. A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study to Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 $94,222 15 payments
3. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $53,675 10 payments
4. A Phase 2B Multicenter Randomized Doubleblind Placebocontrolled Doseranging Study to Evaluate the Efficacy Safety and Pharmacokinetics of Pf06480605 in Adult Participants With Moderate to Severe Ulcerative Colitis $41,402 19 payments
5. Bli4900-302 $31,744 9 payments
6. A Phase 2B Doubleblind Randomized Placebocontrolled Parallel Group Dose Ranging Study of Oral Pf06651600 and Pf06700841 As Induction and Chronic Therapy in Subjects With Moderate to Severe Ulcerative Colitis $20,586 12 payments
7. Efficacy and Safety APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) $18,000 2 payments
8. A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes in Nonresponders With Moderately to Severely Active Ulcerative Colitis (Enterpret) $16,173 5 payments
9. A Phase 2B Randomized Doubleblind Parallelgroup Placebocontrolled Study With An Open Label Extension to Evaluate the Safety and Efficacy of Pf06826647 in Participants With Moderate to Severe Ulcerative Colitis $13,850 2 payments
10. A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $10,750 2 payments

1. Other $101,255 14 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.